Neogen SVP granted 261,210 stock options
Neogen Corporation reported that a senior vice president received new equity awards on 01/07/2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Neogen Corporation reported that a senior vice president received new equity awards on 01/07/2026. The officer was granted 261,210 stock options with a conversion price of $7.38 per share, exercisable until 01/07/2036, covering 261,210 shares of common stock.
In addition, the officer acquired 50,813 shares of common stock linked to options and RSUs and another 50,813 shares tied to PSUs, both at a reference price of $7.38 per share. The options and RSUs vest in three equal annual installments, while the PSUs vest in full at the end of the three-year anniversary of the grant.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock (Right to Buy) | 261,210 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 50,813 | $7.38 | $375K |
| Grant/Award | Common Stock | 50,813 | $7.38 | $375K |
Footnotes (2)
- F1. Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants
- F2. PSUs vest in total at the end of the three year anniversary date of the grant
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider equity awards were reported for NEOG on this Form 4/A?
How many Neogen (NEOG) stock options were granted to the officer?
How do the Neogen (NEOG) options and RSUs from this filing vest?
When do the Neogen (NEOG) PSUs from this grant vest?
Is the Neogen (NEOG) insider ownership in this Form 4/A direct or indirect?
AI-generated analysis. How Rhea-AI works. Not financial advice.